March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Observation of Human Retinal Remodeling in Octogenarians with Resveratrol+
Author Affiliations & Notes
  • Stuart P. Richer
    Eye Clinic 112E, Capt James Lovell Fed Hlth Care Center, North Chicago, Illinois
    RFUMS / Chicago Medical School, Department Preventive and Family Medicine, North Chicago, Illinois
  • William R. Stiles
    Eye Clinic 112E, Capt James Lovell Fed Hlth Care Facility, North Chicago, Illinois
  • Lawrence Ulanski, II
    Eye Clinic 112E, Capt James Lovell Fed Hlth Care Facility, North Chicago, Illinois
    Retina Service, Eye and Ear Infirmary, University of Illinois, Chicago, Illinois
  • Carla Thomas
    Eye Clinic 112E, Capt James Lovell Fed Hlth Care Center, North Chicago, Illinois
  • Footnotes
    Commercial Relationships  Stuart P. Richer, Travel (R); William R. Stiles, None; Lawrence Ulanski, II, None; Carla Thomas, Resveratrol Partners (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 286. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stuart P. Richer, William R. Stiles, Lawrence Ulanski, II, Carla Thomas; Observation of Human Retinal Remodeling in Octogenarians with Resveratrol+. Invest. Ophthalmol. Vis. Sci. 2012;53(14):286.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Spontaneous remissions from age related macular degeneration (AMD) suggest the human retina has large regenerative capacity, even in advanced age. In 2009, we reported resolution of 5 measures of visual function in an 80-year old male with dry AMD placed on a stabilized low-dose resveratrol (RV+) based supplement: (Richer SP, Stiles W. Molecular Medicine in Ophthalmic Care. Optom 2009; 80: 695- 71).

 
Methods:
 

The OTC supplement RV+ was suggested to multiple patients with dry and wet AMD, who progressed on AREDS II type supplements or refused intra-vitreal injections. Patients were clinically followed with high resolution 10 raster SD OCT (OptoVue) & vision function tests:

 
Results:
 

We present 3 notable observations of short-time-frame dramatic improvement in retinal anatomy.CASE 1 (Top): 75 y/o with AMD L foveal occult mb with better VA in 5 days and a driver’s license after 7 days.CASE 2 (Middle): 86 y/o with medically unresponsive L retinal edema , reads at 21 days and has 7 lines better VA.CASE 3 (Bottom): 88 y/o w AMD refusing Lucentis® and sees faces and reads magazines at 14 days.

 
Conclusions:
 

RV+ is used in cardiology to prevent reperfusion injury. It was suggested to retinal patients because its components are known to ↓ Inflammation (COX-2, CRP); ↓ HIF-1 & VEGF genes (microRNA 21, 20b, 539); ↑ Nrf2 endogenous antioxidants (glutathione); ↓ Blood clotting (platelet stickiness); ↑ Vasodilation (nitric oxide); ↑ Metal chelation (iron, copper); ↓ Oxidation, peroxidation; ↓ Cell adhesion (platelets, microbes, tumor) and ↓ Calcification (i.e. Bruch’s membrane). Octogeneraian AMD patients who take 1 oral capsule of RV+ per day often quickly demonstrate anatomic retinal regeneration as well as bilateral improved vision.  

 
Keywords: regeneration • retina • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×